Use of Minocycline in Intracerebral Hemorrhage

Intracerebral Hemorrhage Clinical Trial

Official title:

Minocycline and Matrix Metalloproteinase Inhibition in Acute Intracerebral Hemorrhage: A Pilot Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03040128
• Other study ID #: MITCH
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: January 25, 2017
• Last updated: January 30, 2017
• Start date: June 27, 2013
• Est. completion date: November 30, 2016

Study information

• Verified date: January 2017
• Source: University of Tennessee Health Science Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To date, no neuroprotective drugs have demonstrated clinical efficacy in intracerebral hemorrhage (ICH). This study will use intravenous (IV) minocycline in ICH to evaluate for (1) safety/ tolerability and (2) evaluate for clinical efficacy

Description:

Intracerebral hemorrhage (ICH) remains a devastating neurological disorder with high mortality and poor prognosis with unchanged mortality rates (53-59%). Acute treatment options for ICH remain supportive with no available effective drug or surgical therapy. All trials so far have failed to improve clinical outcome in randomized, double-blinded trials. However, one area of interest has been maintaining the integrity of the blood-brain-barrier (BBB) and preventing the growth of vasogenic edema. Matrix metalloproteinases (MMP) are a family of ubiquitous zinc-dependent endopeptidase enzymes whose primary function is the digestion of collagen type IV, laminin, and fibronectin for the purpose of remodeling extracellular basal lamina. Elevated MMP-9 as a pathological process associated with larger hematoma volume, larger perihematomal edema, and poorer clinical outcome in intracerebral hemorrhage is well documented in animal models and patients. One particular MMP-9 inhibitor gaining usage in cerebrovascular disease is minocycline. Normally FDA-approved for bacterial infection and acne vulgaris, minocycline has also been found to be both a safe and effective treatment in ischemic stroke; its potential role as a neuroprotectant in ischemic stroke is currently being tested in a large, randomized, double-blinded trial. Minocycline's beneficial role as a neuroprotectant may also extend to ICH. By inhibiting MMP-9, minocycline may decrease BBB permeability, resulting in less perihematomal edema and decreased mass effect. Although numerous animal ICH models support minocycline's role as an inhibitor of MMP-9 and neuroprotectant, its use has never been studied in humans with ICH.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 30, 2016
• Est. primary completion date: November 30, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria:

1. Age 18-80 yo

2. Acute neurological deficit with corresponding ICH noted on head CT

3. Glasgow Coma Scale (GCS) > 8

4. Onset of symptoms within 12 hrs

5. < 30 ml of blood noted on initial CTH (30 ml hematoma volume is a noted independent marker between good and poor clinical outcome)

6. ICH score < 3

7. English/ Spanish speaking

Exclusion Criteria:

1. Allergy to tetracycline and tetracycline analogues

2. Pregnancy or suspected pregnancy

3. Hepatic and/or renal insufficiency (LFTs 3x greater than upper limit of normal; creatinine > 2 mg/dL)

4. Thrombocytopenia (plt count < 75,000)

5. History of intolerance to minocycline

6. Baseline modified Rankin score > 1

7. Stuporous or comatose (GCS < 8)

8. Presence of concomitant serious illness that would confound study, including serious psychiatric disease or prior suicide attempts.

Related Conditions & MeSH terms

• Cerebral Hemorrhage
• Hemorrhage
• Intracerebral Hemorrhage

Intervention

Drug:
• Minocycline
high-dose, intravenous minocycline

Other:
• normal saline infusion

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Tennessee Health Science Center	University of Southern California

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with Treatment-related Adverse Effects	Treatment-related adverse effects as noted by package insert: fever, nausea, vomiting, C-diff, hepatic toxicity, dermatitis, anaphylaxis, renal injury)	day 90
Secondary	Volume (ml) of Perihematomal Edema	Volumetric analysis (ml) computed from computed tomography head	Change from baseline perihematomal edema volume to chronic (day 5-11) perihematomal edema volume
Secondary	modified Rankin score	modified Rankin score (points ranging from 0 to 6)	day 90
Secondary	Barthel Index	Barthel Index score (points ranging from 0 to 100)	day 90
Secondary	National Institutes of Health Stroke Scale Score	National Institutes of Health Stroke Scale Score (points ranging from 0 to 42)	day 90
Secondary	Glasgow Coma Score	Glasgow Coma Score (points ranging from 3 to 15)	day 90